Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.

Journal Article

The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.

Full Text

Link to Item

Duke Authors

McLendon, Roger Edwin

Cited Authors

Doolittle, ND; Abrey, LE; Ferrari, N; Hall, WA; Laws, ER; McLendon, RE; Muldoon, LL; Peereboom, D; Peterson, DR; Reynolds, CP; Senter, P; Neuwelt, EA

Published Date

June 2002

Published In

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

Volume / Issue

8 / 6

Start / End Page

1702 - 1709

PubMed ID

12060607

International Standard Serial Number (ISSN)

1078-0432

Language

Conference Location

United States